Gilead Sciences, Inc. (GILD) reported better-than-expected results in the second quarter and raised its annual earnings guidance.Adjusted earnings per share (EPS) of $2.01 comfortably beat the Zacks Consensus Estimate of $1.61. In the year-ago quarter, the company reported adjusted earnings of $1.34 per share.The year-over-year increase was driven by higher revenues and lower operating expenses.Total revenues of $6.9 billion beat the Zacks Consensus Estimate of $6.6, primarily due to high HIV, oncology and ...